Randomized Clinical Trial To Compare Recurrence After Pterygium Removal Between Platelet-Rich Fibrin Graft And Amniotic Membrane
Published 2022
- 40th Congress of the ESCRS
Reference: PP03.03
| Type: Free paper
| DOI:
10.82333/ng8p-4a76
Authors:
Mohammed Alhayek* 1
, Zoraida Del Campo Carrasco 2
1Ophthalmology,Palamos Hospital,Palamos,Spain, 2Ophthalmology,Santa Creu and Sant Pau Hospital,Barcelona,Spain
Purpose
The objetive of this trial is to compare the postoperative
Setting
Surgical removal of pterygium with conjunctival autograft cannot always be carried out when not enough conjunctival tissue is available. In this case, there are other therapeutic options such as amniotic membrane (AM) graft or platelet-rich fibrin (PRF) graft. For this reason, it is necessary to evaluate the most appropriate therapeutic alternative to conjunctival autograft.
Methods
Randomized clinical trial, we enrolled a total of 105 eyes (93 patients), who underwent pterygium excision between January 2019 and Jun 2020. 49 eyes (46.6%) underwent PRF graft and 56 eyes (53.33%) underwent AM graft surgery. All surgeries in both groups were realized by the same surgeon
Results
The mean of follow up time after surgery was 10,32 mounths in (PRF) graft group and 11,06 mounthes in AM group (p=0,34). No significant differences in socio-demographic, clinical and surgical variables were observed between both groups. First we verified that there was no significant difference in the size of the conjunctival defect left after the excision between both groups (mean = 104 ± 27 mm2 in intervention group and 103.39 ± 32.56 mm2 in control group, p = 0.49). There were no significant differences in the postoperative recurrence rate between intervention group and the control group with 7 subjects (14.3%) and 4 subjects (7.1%) respectively, p = 0.34).
Conclusions
No significant differences were found in recurrence rates, between AM graft and (PRF) graft used in
pterygium surgery.